Diclofenac cholestyramine 75 mg
Lithium, digoxin: this medicine may increase plasma concentrations of lithium and digoxin.
Diuretics: As with other NSAIDs this medicine may inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with elevated serum potassium levels, which should be monitored.
NSAIDs: Concomitant administration of systemic NSAIDs may increase the frequency of adverse reactions.
Anticoagulants: Although clinical investigations do not suggest that this medicine present influence on the effect of anticoagulants, there are reports of elevation in the risk of bleeding with the combined use of diclofenac and anticoagulant therapy. Consequently, in such cases, we recommend monitoring of patients.
Antidiabetic: Clinical studies showed that this medicine can be administered simultaneously with oral antidiabetic agents without influencing their clinical effects. However, there are isolated reports of hypo-and hyperglycemic effects that require dose adjustments of hypoglycemic agents during treatment with this medicine.
Methotrexate: Caution should be exercised when NSAIDs are administered less than 24 hours before or after treatment with methotrexate, since the serum concentration of the drug may rise, thus increasing their toxicity.
Cyclosporine: The effects of NSAIDs on renal prostaglandins may increase the nephrotoxicity of cyclosporine.
Quinolone antibacterials: There have been isolated reports of convulsions which may be associated with concomitant use of quinolones and NSAIDs. Concomitant administration of corticosteroids or other anti-inflammatory medications increases the risk of gastrointestinal bleeding. Medication administration assistant aspirin causes decreased serum concentrations of diclofenac.